| Product Code: ETC088685 | Publication Date: Jun 2021 | Updated Date: Jun 2026 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The Jordan Radiopharmaceutical Market was estimated at USD 1103 Million in 2025 and is projected to reach USD 1595 Million by 2032, growing at a CAGR of 5.4% from 2026 to 2032. This upward trajectory is largely fueled by an increasing prevalence of cancer and cardiovascular diseases, which necessitate advanced diagnostic and therapeutic procedures. Moreover, the rising investments in healthcare infrastructure and the collaboration between pharmaceutical firms and research institutions are further stimulating demand for innovative radiopharmaceuticals within the Jordanian healthcare landscape.
The Jordan radiopharmaceutical market has shown a stable growth pattern, with growth rates of 6.4% in 2021, rising slightly to 6.6% in 2022, before moderating to 6.2% in 2023. Factors contributing to this resilience include increased investments in healthcare infrastructure and a growing emphasis on advanced medical technologies. As Jordan continues to focus on enhancing its healthcare services, demand for radiopharmaceuticals is expected to rise, stabilizing around 6.3% to 6.6% through 2031. Fluctuations in growth rates are influenced by periodic policy reforms aimed at improving patient access and regulatory conditions, ultimately fostering a more vibrant market environment.
This graph highlights how the Jordan Radiopharmaceutical Market has steadily grown over the past five years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | 6.4% | Radiopharmaceutical manufacturing upgrades drive local supply chain enhancements |
| 2022 | 6.6% | Domestic radiopharmaceutical manufacturing investments boosted production capacity utilization rates |
| 2023 | 6.2% | Export driven radiopharmaceutical production upgrades bolstered facility modernization efforts |
| 2024 | 6.1% | Upgraded reactor systems boosted local radiopharmaceutical production capacity |
| 2025 | 6.3% | Technology integration improved radiopharmaceutical production line efficiency |
| 2026 | 6.4% | Domestic radiopharmaceutical production capacity expansion supports local healthcare supply chain |
| 2027 | 6.1% | Local radiopharmaceutical facilities upgrade equipment for enhanced production efficiency |
| 2028 | 6.2% | Manufacturing investments in nuclear medicine facilities enhance local production capacity |
| 2029 | 6.5% | Accelerated reactor upgrades enhanced capacity for radiopharmaceutical production |
| 2030 | 6.6% | Local production capacity upgrades boost Jordan's radiopharmaceutical output |
| 2031 | 6.6% | Domestic radiopharmaceutical manufacturing upgrades enhance export capabilities and efficiency |
| 2032 | 6.2% | Domestic radiopharmaceutical production scale up supports regional healthcare infrastructure development |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.
The Jordan Radiopharmaceutical Market is currently witnessing a significant transformation, characterized by a burgeoning demand for nuclear medicine applications. This is particularly evident in the rising number of nuclear medicine procedures aimed at more effective diagnoses and treatments for patients with complex health issues.
As healthcare providers increasingly adopt advanced imaging technologies, the market is poised for dynamic growth. Enhanced collaboration between local players and international partners is further enriching the market by fostering innovation and improving access to radiopharmaceuticals, paving the way for tailored treatment solutions.
While the Jordan Radiopharmaceutical Market shows promise, several restraints hinder its full potential. Regulatory hurdles, particularly around licensing and product approvals, pose significant challenges for companies operating in this sector. Furthermore, there exists a limited availability of advanced imaging technologies, which could impede the integration of cutting-edge radiopharmaceuticals into healthcare practices. High setup and maintenance costs for radiopharmaceutical facilities also restrict the growth of new entrants. Additionally, ensuring specialized training for healthcare professionals is essential to safely handle these complex products, highlighting the need for a concerted effort to address these limitations.
Several trends are reshaping the Jordan Radiopharmaceutical Market, with a notable shift towards personalized medicine and theranostics. Healthcare providers are increasingly focused on delivering precise treatments tailored to individual patient needs. Moreover, the rise of collaborations between domestic and international companies is fostering innovative research and development efforts. These partnerships aim to address the pressing need for advanced and targeted radiopharmaceuticals, which are becoming essential in the fight against diseases.
The market presents a wealth of investment opportunities, especially in the realm of manufacturing facilities designed to cater to the growing demand for radiopharmaceutical products. Collaborating with local healthcare institutions to enhance access to imaging services stands out as another significant avenue for growth. Furthermore, there is a compelling case for investing in research and development activities that introduce innovative radiopharmaceutical solutions tailored to the unique needs of the Jordanian market, offering a pathway for long-term returns.
The Jordanian government has been proactive in implementing regulatory policies aimed at nurturing the radiopharmaceutical market. The Jordan Food and Drug Administration (JFDA) oversees the import, export, and distribution of radiopharmaceuticals, ensuring that safety and quality standards are maintained. By establishing guidelines that prevent price gouging, the government aims to enhance affordability for patients while promoting a competitive market environment. Initiatives to improve healthcare infrastructure further underscore the government’s commitment to advancing nuclear medicine within the country.
Looking ahead to the period from 2026 to 2032, the Jordan Radiopharmaceutical Market is expected to experience sustained growth driven by escalating incidences of cancer and other chronic diseases. The ongoing advancements in radiopharmaceutical technology will likely enhance the effectiveness of diagnosis and treatment, aligning with the global trend towards more personalized healthcare solutions. Additionally, increasing collaborations between research institutions and healthcare providers are expected to foster innovation, thus widening the scope and availability of radiopharmaceutical products in Jordan.
Recent developments within the Jordan Radiopharmaceutical Market indicate a growing emphasis on enhancing the research and development of innovative products. Companies are increasingly focusing on strategic partnerships to facilitate technological advancements and improve the integration of radiopharmaceuticals in clinical settings. These shifts aim to meet the rising demand for effective diagnostic and therapeutic solutions while ensuring compliance with regulatory standards.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Jordan Radiopharmaceutical Market Overview |
3.1 Jordan Country Macro Economic Indicators |
3.2 Jordan Radiopharmaceutical Market Revenues & Volume, 2022 & 2032F |
3.3 Jordan Radiopharmaceutical Market - Industry Life Cycle |
3.4 Jordan Radiopharmaceutical Market - Porter's Five Forces |
3.5 Jordan Radiopharmaceutical Market Revenues & Volume Share, By Types, 2022 & 2032F |
3.6 Jordan Radiopharmaceutical Market Revenues & Volume Share, By Applications, 2022 & 2032F |
3.7 Jordan Radiopharmaceutical Market Revenues & Volume Share, By Procedural Volume Assessment, 2022 & 2032F |
3.8 Jordan Radiopharmaceutical Market Revenues & Volume Share, By Source, 2022 & 2032F |
3.9 Jordan Radiopharmaceutical Market Revenues & Volume Share, By End-users, 2022 & 2032F |
4 Jordan Radiopharmaceutical Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic diseases requiring nuclear medicine diagnostics and treatments |
4.2.2 Growing adoption of nuclear medicine in Jordan's healthcare sector |
4.2.3 Technological advancements in radiopharmaceutical production and imaging techniques |
4.3 Market Restraints |
4.3.1 High cost associated with radiopharmaceutical production and infrastructure |
4.3.2 Regulatory challenges and stringent approval processes for radiopharmaceuticals in Jordan |
5 Jordan Radiopharmaceutical Market Trends |
6 Jordan Radiopharmaceutical Market, By Types |
6.1 Jordan Radiopharmaceutical Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 Jordan Radiopharmaceutical Market Revenues & Volume, By Types, 2022-2032F |
6.1.3 Jordan Radiopharmaceutical Market Revenues & Volume, By Diagnostic Nuclear Medicine, 2022-2032F |
6.1.4 Jordan Radiopharmaceutical Market Revenues & Volume, By Therapeutic Nuclear Medicine, 2022-2032F |
6.2 Jordan Radiopharmaceutical Market, By Applications |
6.2.1 Overview and Analysis |
6.2.2 Jordan Radiopharmaceutical Market Revenues & Volume, By Diagnostic Applications, 2022-2032F |
6.2.3 Jordan Radiopharmaceutical Market Revenues & Volume, By Therapeutic Applications, 2022-2032F |
6.3 Jordan Radiopharmaceutical Market, By Procedural Volume Assessment |
6.3.1 Overview and Analysis |
6.3.2 Jordan Radiopharmaceutical Market Revenues & Volume, By Diagnostic Procedures, 2022-2032F |
6.3.3 Jordan Radiopharmaceutical Market Revenues & Volume, By Therapeutic Procedures, 2022-2032F |
6.4 Jordan Radiopharmaceutical Market, By Source |
6.4.1 Overview and Analysis |
6.4.2 Jordan Radiopharmaceutical Market Revenues & Volume, By Nuclear Reactors, 2022-2032F |
6.4.3 Jordan Radiopharmaceutical Market Revenues & Volume, By Cyclotrons, 2022-2032F |
6.5 Jordan Radiopharmaceutical Market, By End-users |
6.5.1 Overview and Analysis |
6.5.2 Jordan Radiopharmaceutical Market Revenues & Volume, By Hospitals, 2022-2032F |
6.5.3 Jordan Radiopharmaceutical Market Revenues & Volume, By Ambulatory Surgical Centers, 2022-2032F |
6.5.4 Jordan Radiopharmaceutical Market Revenues & Volume, By Diagnostic Centers, 2022-2032F |
6.5.5 Jordan Radiopharmaceutical Market Revenues & Volume, By Cancer Research Institutes, 2022-2032F |
6.5.6 Jordan Radiopharmaceutical Market Revenues & Volume, By Others, 2022-2032F |
7 Jordan Radiopharmaceutical Market Import-Export Trade Statistics |
7.1 Jordan Radiopharmaceutical Market Export to Major Countries |
7.2 Jordan Radiopharmaceutical Market Imports from Major Countries |
8 Jordan Radiopharmaceutical Market Key Performance Indicators |
8.1 Number of nuclear medicine procedures performed annually |
8.2 Investment in research and development for new radiopharmaceutical products |
8.3 Adoption rate of new radiopharmaceutical technologies in Jordan's healthcare facilities |
9 Jordan Radiopharmaceutical Market - Opportunity Assessment |
9.1 Jordan Radiopharmaceutical Market Opportunity Assessment, By Types, 2022 & 2032F |
9.2 Jordan Radiopharmaceutical Market Opportunity Assessment, By Applications, 2022 & 2032F |
9.3 Jordan Radiopharmaceutical Market Opportunity Assessment, By Procedural Volume Assessment, 2022 & 2032F |
9.4 Jordan Radiopharmaceutical Market Opportunity Assessment, By Source, 2022 & 2032F |
9.5 Jordan Radiopharmaceutical Market Opportunity Assessment, By End-users, 2022 & 2032F |
10 Jordan Radiopharmaceutical Market - Competitive Landscape |
10.1 Jordan Radiopharmaceutical Market Revenue Share, By Companies, 2025 |
10.2 Jordan Radiopharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here